/AI Therapeutics
Invite

Pending to review

Not sure yet

Interested

Not interested

Showing 104 companies

Get more companies

Download list

Company
Fit assessment
Description
Subspaces
Tags
HQ Location
Founded
Employees
Total Funding Raised
Last Funding Event
Received on
Top picks for your space

Receptor.AI leverages machine learning and AI technologies to discover new drug candidates and expand therapeutics, optimizing the drug discovery process.

Receptor.AI is a TechBio company developing generative AI techniques to design first-in-class therapeutics. Its multi-platform ecosystem is built to address challenging protein targets using a multimodal approach, allowing for the design of oral compounds with optimal biological activity and bioavailability. Peptides Platform: AI-guided de novo design and optimization of linear and cyclic peptides against challenging targets, including “undruggable” protein-protein interactions. Small molecule Platform: De novo AI-driven design of small molecules by leveraging key interactions related to biological activity with multiparametric optimization of over 80 drug properties. Induced Proximity Platform Engineering ternary complexes to transform structurally unresolved native and induced PPIs into druggable targets. Multilevel AI-driven Drug Discovery Infrastructure: Our drug discovery infrastructure consists of four hierarchical levels that facilitate seamless AI-driven preclinical drug discovery pipeline. Advanced data acquisition, generation and augmentation backs up state-of-the-art predictive and generative AI models for all major drug discovery tasks. These models empower dedicated workflows for different drug modalities and target classes. The whole discovery process is supervised and orchestrated by LLM agents that blend together human expertise and artificial intelligence.
  • Drug Discovery Optimization
Light Search
London (United Kingdom)202111 - 50$11.79MUndisclosed, $11.29M, November 13, 2024
8 months ago

Pepticom leverages machine learning to discover innovative peptide therapeutics, optimizing the drug discovery process and expanding therapeutic options.

Pepticom is a privately held AI company with headquarters in Israel committed to offering AI peptide drug discovery solutions for a better and healthier world. It is the leader in the emerging peptide drugs software solutions, AI and prediction tools that allow research centers, pharma and agriculture companies to accelerate innovative molecules discovery while reducing time, costs and risks. Pepticom operates in various markets; past successful discoveries include peptide molecules related to metabolic diseases and Immuno-modulators.
  • Drug Discovery Optimization
Light Search
Jerusalem (Israel)201111 - 50$14.20MSeries A, $6.60M, January 7, 2025
8 months ago

Genix.ai effectively leverages machine learning for clinical investigations, discovering patterns in genomic data, and expanding therapeutic strategies for personalized medicine.

Genix.ai is a machine learning-assisted clinical investigation service using next-generation sequencing(NGS) and biomedical imaging data. They are providing personalized treatment strategies for clinicians with timely detection of biomarkers to fight rare diseases in infants, extend and improve the quality of life with cancer patients, and cost-effective detection of complex infections.
  • Genomic Data Analysis
Light Search
Tiruchirappalli (India)20211 - 10NA
8 months ago

Delta 4 effectively utilizes machine learning for drug discovery, identifies new patterns in drug-disease relationships, and expands therapeutic options through drug repurposing.

Delta 4 is a Vienna-based biotech startup driving the forefront of digital drug discovery and development. Delta 4 leverages on a proprietary computational analytics platform, combined with straightforward biomedical testing and clinical validation of candidate drugs. Our unique approach integrates iterative big data/in silico and experimental screens, offering most efficient matching of clinical indications and compound/drug effect. Our R&D process allows a fast track to clinical stage testing; our methodological core is tailored toward precision for increasing probability of success.
  • Drug Repurposing
  • +1
Light Search
Vienna (Austria)201811 - 50Series A, April 7, 2021
8 months ago

OutSee leverages machine learning for genomic data analysis, discovering patterns and expanding therapeutic approaches in drug development.

OutSee creates cutting-edge computational methods for genomics for the development of therapeutic targets and precision medicine.
  • Genomic Data Analysis
Light Search
Cambridge (United Kingdom)20221 - 10NA
8 months ago

10x Genomics develops advanced DNA sequencing technology and innovative tools for analyzing biological systems, enabling researchers to uncover complex cellular interactions and gene expression patterns in various fields, including oncology and immunology. Their product portfolio includes instruments, consumables, and software designed to enhance scientific discovery.

10x Genomics is creating revolutionary DNA sequencing technology to help researchers better identify subtle variations that are overlooked by technologies that shred biological samples into tiny fragments before sequencing the short stretches and using computers to assembling them into a genome.
  • Genomic Data Analysis
Light Search
Pleasanton (United States)20121001 - 5000$632.60MPost-IPO Equity, January 1, 2020
8 months ago

AIA Insights leverages machine learning and AI algorithms in its Drug Engine platform to enhance drug discovery, identify new therapeutic candidates, and streamline the research process.

Provider of AI-aided drug discovery solutions designed to increase company value, accelerate research, and reduce costs for Pharma SMEs and academic institutions. The company offers a platform called Drug Engine, which integrates AI, data science, and collaboration tools to facilitate early drug discovery research. The entity consists of experts in drug discovery, AI, and bioinformatics.
  • Drug Discovery Optimization
Light Search
1 - 10NA
8 months ago

NonExomics leverages machine learning to discover new patterns in genomic data and expand therapeutics for rare diseases.

NonExomics integrates genomics, transcriptomic, and proteomics data by utilizing proprietary machine learning approaches to predict structures of nonexomic proteins and identifies disease-specific nonexomic targets, allowing clients to find cures for rare diseases.
  • Genomic Data Analysis
Light Search
Acton (United States)20211 - 10$200.00KNon-Equity Assistance, March 16, 2022
8 months ago

OpenDNA effectively leverages machine learning for genomic data analysis, enabling personalized treatment strategies and discovering new patterns in genetic risks.

Operator of a biotechnology company offering genetically personalized medicine for chronic multi-gene diseases. The company's platform uses precision genomic AI that combines clinical and genomic data for detailed analysis of heart diseases, and its prediction models help identify high-risk patients and their key prevention strategies, enabling physicians to easily prescribe the genetically fit treatment to their patients at the point of care.
  • Genomic Data Analysis
Light Search
Gaithersburg (United States)20181 - 10NA
8 months ago

Pinnacle leverages machine learning and genomic AI to discover patterns and expand therapeutics, making it a strong fit for the specified requirements.

Pinnacle provides a canonical interface to data points and genomic artificial intelligence to drive precision medicine. They use intelligent technologies and on-demand expertise to drive precision medicine. They give you the data and tools you need to make discoveries, diagnose diseases, and develop NGS applications.
  • Genomic Data Analysis
Light Search
Rochester (United States)20011001 - 5000NA
8 months ago

io9 leverages machine learning to enhance cancer diagnostics and therapeutics, focusing on biomarker identification and pattern discovery.

Operator of AI-driven digital pathology intended for oncology diagnostics. The company utilizes advanced image analysis, molecular profiling and biomarker detection technologies to analyze routine pathology slides, enabling oncologists and healthcare providers to deliver timely, accurate and equitable cancer care.
  • Biomarker Identification
Light Search
San Diego (United States)20211 - 10NA
8 months ago

Vindhya Data Science leverages machine learning for genomic analysis, discovers patterns in biological data, and facilitates drug discovery, making it a strong fit for the requirements.

Operator of a US-based data science company intended to leverage data analysis for impactful life science and drug discovery insights. The company offers expert data analysis in bioinformatics, genomics, and AI, unlocking hidden patterns and trends within complex biological datasets, enabling customers to make informed decisions in drug discovery, biomarker identification, and genomic analysis.
  • Genomic Data Analysis
Light Search
Boston (United States)20211 - 10NA
8 months ago

My Next Health leverages machine learning and genomic data analysis to discover new health patterns and develop personalized therapeutics.

My Next Health builds health applications that provide insights into the prevention and treatment of chronic diseases using a novel approach to functional genomics. These applications allow consumers to self-manage those insights based on their own genetic predispositions, and can help inform their healthcare providers on interventions.
  • Genomic Data Analysis
Light Search
Mississauga (Canada)20181 - 10NA
8 months ago

DNAlytics leverages machine learning to enhance precision medicine, discover patterns, and expand therapeutic options, making it a strong fit for the requirements.

DNAlytics develops innovative data-driven precision medicine solutions (diagnosis, prognosis, treatment guidance) through partnerships with healthcare players such as pharmaceutical, biotechnological or In Vitro Diagnostic (IVD) companies. DNAlytics wants its solutions to have a major impact on patients, healthcare practitioners and Society as a whole. DNAlytics is a Belgian company founded in 2012 as a UCLouvain Spin-Off that bases its activities on a data mining technology platform. Aside from product (co)development, DNAlytics also proposes its expertise in the form of a data mining consultancy service. In this context we serve various types of customers. DNAlytics received various awards, namely from IBM, Microsoft, the European Commission or the MIT, both for its technology and its business model.
  • Genomic Data Analysis
Light Search
Louvain-la-neuve (Belgium)20121 - 10$53.85KGrant, $54.00K, April 1, 2015
8 months ago

Genuity Science leverages machine learning for genomic data analysis, discovering patterns and expanding therapeutic options to improve patient health.

Genuity Science provides clinco-omics data analysis solutions for researchers. They also provide genomic sequence data. Their platform offers study design, sequencing, storage, interpretation, secondary analysis, and scalable analytics, enabling organizations to improve patient health using the human genome.
  • Genomic Data Analysis
Light Search
Boston (United States)201351 - 200$455.00MAcquired, August 2021
8 months ago

PersMed Co. effectively leverages machine learning for genomic data analysis, discovering patterns and expanding therapeutic options in cancer treatment.

PersMed Co., working on analyzing genomic data, with a specific focus on cancer, we are contributing to a field that has the potential to make a significant impact on healthcare. With the increasing availability of genomic data, we are able to study the underlying genetic causes of cancer in unprecedented detail, opening up new possibilities for the development of more effective treatments and prevention strategies. Our work involves analyzing large amounts of genomic data to identify patterns and anomalies that may be associated with cancer. By applying advanced statistical and machine learning techniques to this data, we can uncover important insights into the molecular mechanisms underlying cancer development and progression. Your research has the potential to lead to the development of new diagnostic tools and targeted therapies that can improve patient outcomes and quality of life. By understanding the genetic basis of cancer, we can develop more precise and personalized treatment options that are tailored to each patient's unique genetic profile. Overall, our work in analyzing genomic data for cancer research is an important contribution to the field of healthcare. With our expertise in data analysis and genomics, we are well-positioned to make significant contributions to the development of new cancer treatments and prevention strategies that can improve the lives of millions of people around the world.
  • Genomic Data Analysis
Light Search
Iran20201 - 10NA
8 months ago

StoneWise effectively leverages machine learning and integrates various scientific disciplines to enhance drug discovery, thereby expanding therapeutic options.

StoneWise, founded in 2018, is a technology company committed to accelerating novel drug discovery with artificial intelligence. We intend to use AI technology and innovation to lead a paradigm shift in Drug discovery for the pharmaceutical industry. Our goal is to replace the previous single-engine drug R&D focusing onexperts based model with the new twin-engine drug R&D model with advanced AI technology and expert system. Our platform is designed by cutting-edge technologies such as artificial intelligence and microfluidics, integrated with computational chemistry, computational biology, pharmacology and clinical medicine. The Platform provides pharmaceutical companies with integrated solutions.These solutions include a vast range of tools such as medical knowledge graph,the discovery of priviledged scaffolds,molecular generation and design,as well as predicting reaction products and planning path synthesis.Using this platform,StoneWise hopes to enhancing the efficiency and success rate of early stage drug discovery. StoneWise has engaged a number of domestic and foreign technical experts in the field of Internet, artificial intelligence, pharmaceutical industry and other scientific disciplines. It equips a state of art scientific drug discovery facility, keeps track of latest innovating in drug discovery, and provides its customers with excellent technologies, products and services. StoneWise started to collaborate with domestic and foreign universities, research institutions and pharmaceutical factories.
  • Drug Discovery Optimization
Light Search
Haidian (China)201851 - 200$110.00MSeries B, $100.00M, April 12, 2021
8 months ago

REPO-TRIAL effectively leverages machine learning to discover new therapeutic uses for existing drugs, enhancing their value and application in clinical settings.

Our project develops a computerized (in silico) approach to optimise the efficacy and precision of drug repurposing trials. De novo drug design requires 10 to 15 years until market entry. We want to help patients faster and more efficiently. In comparison to de novo drug design, drug repurposing can happen much faster, costs less, and imposes a lower risk. The time for validation of a known drug’s potential new purpose is significantly reduced because less or no animal experiments are required, clinical studies can be conducted sooner, potential side effects are already known. So far, finding a new use for an old drug (drug repurposing) has been a serendipitous process. REPO-TRIAL aims to improve the efficacy and precision of predicting new purposes for registered drugs by using a revolutionary in silico approach. We use computer-based algorithms and an innovative definition of diseases to screen for potentially beneficial effects of registered drugs in mechanistically related disease phenotypes. We then validate promising in silico-repurposed candidate drugs up to the clinical level. The algorithms that we use to identify mechanistically related disease phenotypes may include completely different organs or areas of the human body than the original was used for. This systems-based (integrative / whole-body) approach will create “virtual patient cohorts”. Finally, we will validate in silico repurposed drugs in actual clinical studies with real patients and high precision. Because validation of all new drug repurposing opportunities would be unrealistic, we will focus on a patient cohort that the REPO-TRIAL consortium understands very well (a) metabolic and cerebrocardiovascular disease phenotypes, such as stroke, diabetes or Alzheimer’s, or b) patients that are positive for a specific panel of diagnostic blood biomarkers that can be measured in the laboratory). REPO-TRIAL will provide rapid patient benefits, reduce drug development time & costs, and reduce risks.
  • Drug Repurposing
Light Search
Netherlands201851 - 200NA
8 months ago

Acutis Biosciences leverages machine learning for biomarker discovery and supports the development of new therapeutics, enhancing precision medicine.

Acutis Biosciences is a subsidiary Contract Research Organization (CRO) under the ownership of Acutis. At Acutis Biosciences, we are reimagining biomarker discovery at the intersection of DNA, RNA, and protein diagnostics, and rewriting the rules to champion our biopharma partners. Our focus isn't just pioneering drug discovery and development; it's also forging an era of service excellence, setting a new standard in the industry to elevate precision medicine to another level. We specialize in enabling biopharmaceutical companies to discover biomarkers through advanced multi-omics analysis solutions powered by machine learning (ML) and artificial intelligence (AI). Our technology platforms in genomics and histopathology support our partners in development and validation of state-of-the-art cancer molecular diagnostic assays, in oncology, immuno-oncology and infectious diseases. Leading pharmaceutical and biotech companies trust us to deliver 11-star service coupled to extraordinary science. Learn more: www.acutisbiosciences.com
  • Biomarker Identification
Light Search
United States202251 - 200NA
8 months ago

e-NIOS leverages machine learning for genomic data analysis, enabling the discovery of new patterns and the development of novel therapeutics.

e-NIOS develops a platform for unsupervised analysis and interpretation of Genomics data of multiple sources (multi -omics), with applications in Biotechnology, Drug Discovery and Personalized Medicine.
  • Genomic Data Analysis
  • +1
Light Search
Kallithéa (Greece)20141 - 10$233.37KSeed, $109.00K, January 10, 2016
8 months ago

The company effectively leverages machine learning for biomarker identification and the development of new therapeutic strategies, enhancing personalized medicine in oncology.

Operator of a biotechnology company intended for precision medicine in oncology. The company specializes in tumor characterization via high-resolution proteomic profiling via the combined use of mass spectrometry imaging and machine learning algorithms and it focuses on personalized medicine by offering patients the right treatment at the right time, especially for poor-prognosis cancers like digestive cancers, enabling healthcare industry to save patient's lives and reduce the cost of expensive inefficient treatments.
  • Biomarker Identification
Light Search
Paris (France)20221 - 10Non-Equity Assistance, May 1, 2024
8 months ago

Javelin Biotech effectively leverages machine learning and pattern discovery to enhance drug discovery and expand therapeutic options.

Javelin Biotech is a framework for predictive drug discovery designed to improve drug performance prediction in humans. The company's platform enables biopharmaceutical companies to optimize ADME(T) and PD properties, which improve drug discovery and approval of the same, by bringing human-relevant in-vitro data and computational biology or data analytics to pre-clinical drug discovery teams. This accelerates preclinical drug discovery and development by finding human-relevant targets.
  • Drug Discovery Optimization
Light Search
Woburn (United States)201811 - 50Pre-Seed, January 1, 2019
8 months ago

Quibim is a leader in medical imaging analysis, utilizing AI to enhance the detection of diseases and track treatment efficacy through quantitative imaging biomarkers. Their platform integrates multi-omics data and advanced algorithms to improve patient outcomes in various medical fields, including oncology and immunology.

Quibim, with headquarters in Valencia, Spain, is a global leader in whole-body medical imaging analysis. Quibim products are used worldwide by leading pharmaceutical companies and research teams. Partners use Quibim Precision®, a whole-body imaging ecosystem, for a wide range of applications from detecting a disease to tracking the efficacy of novel treatments. Quibim follows an AI-first approach to help detect pathologies across every body part and imaging modality, using quantitative imaging biomarkers. We understand every body part. We speak human.
  • Biomarker Identification
Light Search
Valencia (Spain)201251 - 200$69.59MSeries A, $50.00M, January 28, 2025
8 months ago

Yunjian leverages machine learning and big data to discover disease markers and expand therapeutics, demonstrating a strong fit for the requirements.

Yunjian is a new generation of metabolomics- and protein-based marker-finding technologies. has developed a distinctive analytic platform based on mass spectrometry proteomics and big data, driven by medical theories that greatly reduce the time required by conventional methods to find disease markers. has a wealth of experience in big data illness models, medication development, disease biomarker identification, clinical translation and diagnostics, and data security.
  • Biomarker Identification
Light Search
Hangzhou (China)201511 - 50$1.29MSeries B, August 19, 2022
8 months ago

Flagship Biosciences leverages machine learning for data analysis, discovers new patterns in biomarker data, and supports drug development, enhancing therapeutic options.

Flagship Biosciences delivers comprehensive tissue profiling for predictive diagnostic applications using our Artificial Intelligence (AI) enabled cTA® pathology platform. Our intuitive data reporting gives researchers, clinicians, and drug developers the actionable information needed to drive better clinical results for patients.
  • Biomarker Identification
Light Search
Westminster (United States)200951 - 200$20.29MVenture - Series Unknown, $5.00M, April 16, 2024
8 months ago